Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder

7 May 2014

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals has released positive results of its schizoaffective relapse prevention study of once-monthly atypical long-acting antipsychotic Invega Sustenna (paliperidone palmitate).

The trial found Invega Sustenna met its primary endpoint of delayed time to and reduced risk of relapse compared to placebo as monotherapy and adjunctive therapy in patients with schizoaffective disorder. Invega Sustenna also showed significant efficacy in manic and depressive mood symptoms and psychosis, and improved and maintained patient functioning.

Data support sNDA filing later this month

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK